Close Menu

The Lancet

Dent in Trust

The Guardian writes that the retraction last week of two COVID-19 papers may affect public trust in science.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

The Lancet's Critique

Lancet editorial criticizes the US pandemic response and the minimization of the Centers for Disease Control and Prevention's role in the response.

The study, the second major clinical validation of the test, was published in the same week that Cepheid reported strong first-quarter results and several financial analysts raised their earnings estimates for the company.

Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.